These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 25516455)

  • 1. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
    Remacha ÁF; Arrizabalaga B; Villegas A; Durán MS; Hermosín L; de Paz R; Garcia M; Diez Campelo M; Sanz G;
    Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
    Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
    Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
    Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
    Zhang Y; Xiao C; Gu SC; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC; Wong SAY; Leitch HA
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.